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Angiotensin I-converting enzyme (ACE), which is a key enzyme of the 
renin-angiotensin system, is one of target for antihypertensive molecules. 
Indeed, ACE is well known for its involvement in hypertension which is the 
main risk factor involved in the development of cardiovascular and kidney dis-
eases and is a major cause of morbidity and mortality. Currently, many pharma-
cological ACE inhibitors (captopril, lisinopril…) are used for hypertension 
treatment, but their administration over a long period is associated with some 
undesirable side effects. Furthermore, there are many publications dealing with 
antihypertensive peptides from food proteins. ACE-inhibitory peptides, gener-
ated by hydrolysis of food proteins, may be a natural alternative to prevent 
hypertension appearance. However, among the bioactive peptides published in 
the literature as ACE inhibitors, a very small number really displays an antihy-
pertensive activity in vivo in animals. Moreover, their mechanism of action at 
the molecular level is still misunderstood. The objective of our work was to 
characterize the molecular interactions between ACE and some peptides 
described as ACE-inhibitors, which have or not a true antihypertensive activity 
in vivo. For this purpose, a methodology already developed in our teams was 
employed (Zidane et al., 2013). It is based on the use, for the first time, of 
Biacore® technology (SPR). This real time technology provides some important 
molecular information such as the rate constants of association and dissociation, 
the stoichiometry and the site of the interaction on ACE. In our study, the direct 
interaction between ACE and inhibitors (without substrate or ligand) showed 
dissociation constants (KD) of the same order of magnitude as IC50. Moreover, 
the formed ACE-inhibitor complexes are unstable. Given these results, it is dif-
ficult to attribute significant antihypertensive effect demonstrated in vivo for 
these peptides (for example IPP, VPP) to the only ACE inhibition.
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Objective: We previously showed (Bobrie et al. J Hypertens 2012) that 
sequential-nephron blockade (SNB) was more effective than combined renin 
angiotensin system blockade (RB) for controlling BP in patients with resistant 
hypertension (RH). In this post-hoc analysis, we assessed medication adher-
ence (MA) and its influence on the antihypertensive response to SNB/RB with 
a new combined scoring system.
Design and Method: Pts with daytime ambulatory SBP/DBP (dASBP/
dADBP) >135 and/or 85 mmHg, despite 4 week-treatment with irbesartan 300 
mg+HCTZ 12.5 mg+amlodipine 5 mg, were randomised either to SNB 
(i.e.+spironolactone 25 mg, then +furosemide 20-40 mg, then +amiloride 5 
mg, n=82) or RB (ramipril 5-10 mg, then bisoprolol 5-10 mg, RB group, 
n=82) for 12 weeks. MA was scored according to 4 criteria: (i) trough/peak 
plasma irbesartan (Irb) concentration (HPLC); (ii) urinary AcSDKP/creatinine 
ratio (UR) to evaluate ramipril intake; (iii) delay of last medication intake 
before visit (LMI); and (iv) pill counting (PC, %). One point of MA score was 
attributed to trough Irb >20ng/ml, UR >4nmol/mmol, LMI <24h and PC 
>80%. MA was defined as low (LMA, score <2), intermediate (IMA, 
score=3), and optimal (OMA, score=4).
Results: 82 pts among 164 had OMA (46 SNB and 36 RB); 52 pts had IMA 
(23 SNB and 29 RB); and 30 pts had LMA (13 SNB and 17 RB) (inter-groups 
difference: NS). LMA pts were younger than SMA pts (50±11 vs. 56±10 yrs, 
p<0.011). In OMA pts, the difference in dASBP/dADBP between SNB vs RB 
was significant (–11 [–17;–6]/–6 [–9;–2] mmHg, p<0.0001/p=0.0025), favoring 
SNB, whereas in LMA pts the significant difference between the two groups was 
no more observed (–6 [–19;7]/–1 [–10;7] mmHg, p=0.352/p=0.7096).
Conclusion: The major BP lowering effect of SNB vs. RB observed in pts 
with OMA is lost in pts LMA. Combined methods for assessing MA allow 
determining the true efficacy of antihypertensive strategies in patients with 
RH. Reinforcement of MA in RH pts is deemed necessary.
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Objective: We have previously shown that combined renin-angiotensin 
system blockade (RB) was less effective than sequential-nephron blockade 
(SNB) for controlling BP in resistant hypertension (RH). Whether this is 
accompanied with an improvement in the mechanical properties of large 
arteries is unknown.
Design and Method: Pts with daytime ambulatory SBP/DBP (dASBP/
dADBP) >135 and/or 85 mmHg, despite 4 week with irbesartan (Irb)+ 
HCTZ+amlodipine, were randomised to SNB (n=82) or RB (n=82) for 
12 weeks. Central pulse pressure (CPP) and carotid-femoral pulse wave 
velocity (PWV) were measured by aplanation tonometry. High-resolution 
echotracking system (Walltrack®) was used to measure carotid artery diam-
eter (Dcca), wall thickness (WT), circumferential wall stress (CWS), and stiff-
ness. All parameters were measured at baseline and week 12.
Results: Baseline clinical characteristics did not differ between groups. 
dASBP decreased more in SNB (–19±12 mmHg) vs RB (–8±13 mmHg, p<10-
6), either for CPP [SNB (–12.8±16.9 mmHg) vs RB (–1.0±9.3 mmHg, 
p<0.006)] after adjustment on baseline CPP and deltaMeanBP. CCA stiffness 
and PWV decreased similarly in both groups. Dcca decreased more in SNB (–
267±46 μm) vs RB (–7.8±39 μm, p=0.01) after adjustment on baseline D and 
deltaASBP. WT did not differ and CWS decreased more in SNB (–15.2±16.5 
kPa) vs RB (–5.2±12.6 kPa, P=0.001).
Conclusions: In RH pts, a ttt strategy based on SNB improved CPP to a 
greater extent than a RB strategy. This may lead to a better target organ damage 
prevention and CV outcome. SNB improved CWS. Whether this effect is due 
aldosterone blockade or sodium depletion remains to be investigated.
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Introduction: This study was designed to evaluate the effect of nebivolol 
(vs. bisoprolol) on the genital circulation, fetal growth and postnatal develop-
ment in wistar rat.
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Materials and methods: 110 pregnant rats were used in this study: 
untreated (control) rats (n=42), rats orally treated with nebivolol (8 mg/kg/day, 
n=43), or bisoprolol (10 mg/kg/day, n=25) from day 11 to day 18 of gestation. 
The systolic blood pressure (SBP) and genital blood flow (GBF) were mea-
sured by tail cuff method and transonic method respectively (on the 19th day 
and 20th of the gestation). In addition, a morphometric study was performed 
on the ovarian and uterine arteries; fetal weight and postnatal development of 
three infants randomly chosen are following for 8 weeks. The results are 
expressed as mean ± SEM of n experiments.
Results: The results clearly showed that SBP and GBF are lower in rats 
treated with nebivolol (SBP=115.56 ± 0.62 mmHg. GBF= 0.20 ± 0.04 ml/s) 
compared to untreated rats (SBP=140.14 ± 0.33 mmHg. GBF=0.53±0.03 ml/s) or 
to that treated with bisoprolol (SBP=122.42 ± 0.28. GBF=0.40±0.03). The 
treatment with nebivolol also caused a strong increase of lengths and diame-
ters of the ovarian and uterine arteries. In addition, it increases the number of 
segmental branches of the uterine artery compared to the other two groups. 
Moreover, the results showed that nebivolol has an adverse impact on fetal 
growth and postnatal development. It was found that average weight of a fetus 
at the end of gestation was (3.55 ± 0.03 g) with nebivolol, (5.64 ± 0.01 g) with 
bisoprolol and (6.05 ± 0.02 g) in control.
Conclusion: We showed that the action of nebivolol is not only limited to 
its favorable hemodynamic effects, but nebivolol also produces adverse effects 
on fetal growth and postnatal development, that may limit its therapeutic use 
during pregnancy. As wistar female rats were normotensive, we need to fur-
ther investigate the effect of nebivolol in a hypertensive model.
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Objective: Hypertension is a frequent side effect of antiangiogenic drugs 
(AAD). Targeting VEGF pathway may also affect large and small artery prop-
erties, along with or independently of blood pressure changes. We hypothe-
sized that large and small artery property changes in response to AAD reflect 
their effect on the microcirculation at the site of the tumor, and thus may be 
related to cancer progression and mortality.
Design and method: We included 60 patients [age 58 (15) years, mean 
SBP 127(21) mmHg] in whom treatment with AAD was indicated for various 
metastatic solid tumors. Noninvasive arterial investigation was performed 
before AAD (V0), 1 week later (V1) and then every two weeks for two 
months (V1 to V4): carotid-femoral pulse wave velocity (cfPWV), central 
SBP and augmentation index (cAIx) by applanation tonometry (Sphyg-
moCor®), and carotid stiffness (CStiff) and internal diameter (CiD) by high 
resolution echotracking (Artlab®). Cancer progression and mortality were 
assessed at 6 months.
Results and conclusion: 28(47%) patients developed hypertension during 
follow-up. bSBP significantly increased during follow-up (V0-V1: +9.3± 
15.2mmHg, P<0.001; V0-V4: +6.0±17.8mmHg, P=0.03), as well as PWV, 
CStiff, and CiD. Baseline cAIx predicted cancer progression (RR=0.73 per 
10%) and mortality (RR=0.73 per 10%, P<0.001) while SBP did not. The V0-
V1 increase in CStiff predicted cancer progression (RR=1.37 per 1 m/s, 
P=0.02), independently of age and MBP. In conclusion, increased AIx and 
arterial stiffness, but not brachial or central SBP, were related with the effects 
of AAD on cancer progression and mortality.
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Introduction: Renal denervation is an endovascular technique of sympa-
thetic afferences ablation, currently indicated in resistant hypertension.
Objective: According to the European guidelines, it should be part of a 
comprehensive therapeutic approach and the object of a multidisciplinary 
decision. To this purpose, we evaluated our professional practices by ana-
lyzing our one-year program of screening for eligible patients.
Patients and Method: Between Oct 2012 and Oct 2013, 10 interdisci-
plinary reunions including vascular doctors, nephrologists, radiologists and 
cardiologists took place at the University Hospital of Strasbourg, reviewing 
41 cases of resistant hypertension.
Results: The characteristics of the 41 patients were the following: a mean 
age of 62±9 years old (mean±SEM), predominantly male (66%), a glomerular 
filtration rate of 67±23 ml/min/1,73 m2 and an ambulatory blood pressure 
(ABPM) daytime mean of 152/83mmHg±15/14 while receiving 4±1 anti-
hypertensive drugs daily. Among them, 9 were controlled after adjustment of 
medical treatment, 5 had a renal artery stenosis, 4 had a fibromuscular dys-
plasia; there were 2 severe renal impairments and 11 other morphologic exclu-
sion criteria. The 10 patients who finally benefitted from renal denervation 
had an initial daytime ABPM of 164/93±11/11 mmHg and an initial office 
blood pressure of 174/94±18/23mmHg while receiving 5,2±0.6 antihyperten-
sive drugs. The follow up visits showed a mean reduction in the office blood 
pressure of 11.5mmHg ±18 at 1 month (n = 9), of 10.5mmHg ±10 at 3 months 
(n = 7) and 14mmHg ±25 at 6 months(n = 5).
Conclusion: Renal denervation is an invasive procedure claiming to 
become part of the armamentarium of antihypertensive treatments, requiring 
trained operators and prior careful evaluation in order to eliminate remediable 
causes of treatment resistance. Our preliminary results are mitigated showing 
a stable and significant resp
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